Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 201

Sort by

Sort Order Select

Journal Articles

Potential future direction of measurable residual disease evaluation in multiple myeloma

Mohamad Mohty, Hervé Avet-Loiseau, Florent Malard, Jean-Luc Harousseau

Blood (2023) 142 (18): 1509–1517.

https://doi.org/10.1182/blood.2023020284

Published: 2023

Includes: Supplemental data

Journal Articles

Sequencing anti-BCMA therapies in myeloma

Jean-Luc Harousseau, Mohamad Mohty

Blood (2023) 141 (3): 211–212.

https://doi.org/10.1182/blood.2022018157

Published: 2023

Journal Articles

Requirements for operational cure in multiple myeloma

Mohamad Mohty, Hervé Avet-Loiseau, Jean-Luc Harousseau

Blood (2021) 138 (16): 1406–1411.

https://doi.org/10.1182/blood.2021012854

Published: 2021

Journal Articles

Up-front ixazomib in older patients with myeloma

Jean-Luc Harousseau, Mohamad Mohty

Blood (2021) 137 (26): 3584–3586.

https://doi.org/10.1182/blood.2021011262

Published: 2021

Journal Articles

Daratumumab in transplant regimens for myeloma?

Jean Luc Harousseau, Mohamad Mohty

Blood (2020) 136 (8): 917–918.

https://doi.org/10.1182/blood.2020006298

Published: 2020

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Light Chain Escape in Multiple Myeloma

Thomas Dejoie, MD, Guillemette Fouquet, Cyrille Hulin, Murielle Roussel, Benjamin Hebraud, Lionel Karlin, MD, Brigitte Kolb, MD, Carla Araujo, MD, Nathalie Meuleman, PhD MD, Mourad Tiab, MD, Jean Valère Malfuson, MD, Pascal Bourquard, MD, Pascal Lenain, MD, Arnaud Jaccard, MD PhD, Karim Belhadj, Gérard Lepeu, MD, Marie Lorraine Chretien, MD, Denis Caillot, Jean Fontan, MD, Philippe Rodon, MD, Anna Schmitt, Laurent Voillat, MD, Sophie Cereja, MD, Brigitte Pegourie, MD, Frederique Kuhnowski, MD, Sophie Rigaudeau, MD, Olivier Decaux, MD, Catherine Humbrecht-Kraut, MD, Jamilé Frayfer, MD, Laurent Garderet, Damien Roos-Weil, MD, Jean Claude Eisenmann, MD, Veronique Dorvaux, MD, Eric G. Voog, MD, Claire Mathiot, MD, Jean-Paul Fermand, MD, Thierry Facon, Hervé Avet-Loiseau, MD PhD, Jean Luc Harousseau, MD, Philippe Moreau, Michel Attal, MD PhD, Xavier Leleu, MD PhD

Blood (2018) 132 (Supplement 1): 1881.

https://doi.org/10.1182/blood-2018-99-112396

Published: 2018

Journal Articles

How I treat first relapse of myeloma

Jean Luc Harousseau, Michel Attal

Blood (2017) 130 (8): 963–973.

https://doi.org/10.1182/blood-2017-03-726703

Published: 2017

Journal Articles

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective

S. Vincent Rajkumar, Jean Luc Harousseau

Blood (2016) 128 (24): 2757–2764.

https://doi.org/10.1182/blood-2016-09-692947

Published: 2016

Journal Articles

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Michel Attal, Valerie Lauwers-Cances, MD, Cyrille Hulin, MD, Thierry Facon, Denis Caillot, Martine Escoffre, Bertrand Arnulf, Margaret MACRO, MD, Karim Belhadj, MD, Laurent Garderet, MD, Murielle Roussel, MD, Claire Mathiot, MD, Herve Avet-Loiseau, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, jean Luc Harousseau, Philippe Moreau

Blood (2015) 126 (23): 391.

https://doi.org/10.1182/blood.V126.23.391.391

Published: 2015

Journal Articles

Comparing the Performance of Serum Free Light Chain Measurements with Urine Electrophoresis and Immunofixation for Monitoring and Assessing Response to Therapy in Patients with Multiple Myeloma

Thomas Dejoie, Michel Attal, Philippe Moreau, MD, Jean-Luc Harousseau, Herve Avet-Loiseau

Blood (2014) 124 (21): 3347.

https://doi.org/10.1182/blood.V124.21.3347.3347

Published: 2014

Journal Articles

Prolonged Fluconazole Prophylaxis Is Not Required In Patients With Acute Leukemias Or Myelodysplastic/Myeloproliferative Disorders After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): A Pair-Matched Analysis

Eolia Brissot, MD, Xavier Cahu, MD, Thierry Guillaume, MD, Jacques Delaunay, MD, Sameh Ayari, Cristina Precupanu, MD PhD, Pierre Peterlin, Jean-Luc Harousseau, MD, Noel Milpied, MD, PhD, Philippe Moreau, MD, Mohamad Mohty, MD, PhD, Patrice Chevallier, MD, PhD

Blood (2013) 122 (21): 4543.

https://doi.org/10.1182/blood.V122.21.4543.4543

Published: 2013

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Jean El-Cheikh, MD PhD, Stéphane Morisset, Stat., Anne Sirvent, MD, Oumedaly Reman, MD, Jérôme Cornillon, MD, Reza Tabrizi, MD, Noel Milpied, MD, Jean-Luc Harousseau, MD, Hélène Labussière-Wallet, MD, Franck E. Nicolini, MD, PhD, Charles Dumontet, M. D., Ph.D., Mohamad Mohty, Michel Attal, MD, Didier Blaise, MD, Philippe Moreau, MD, Hervé Avet-Loiseau, MD, PhD

Blood (2012) 120 (21): 3116.

https://doi.org/10.1182/blood.V120.21.3116.3116

Published: 2012

Journal Articles

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Blood (2012) 120 (21): 749.

https://doi.org/10.1182/blood.V120.21.749.749

Published: 2012

Journal Articles

The Combination of ISS 3, High LDH and t(4;14) and/or Del(17p) Identify a Simple Prognostic Index for Overall Survival in Patients Treated with Novel Agents-Based Induction Therapy and Front-Line Autologous Stem Cell Transplantation, and Allow the Definition of a Subgroup of Patients At High-Risk of Early Death From Progressive Disease

Blood (2012) 120 (21): 598.

https://doi.org/10.1182/blood.V120.21.598.598

Published: 2012

Journal Articles

Proteasome inhibitors in multiple myeloma: 10 years later

Philippe Moreau, Paul G. Richardson, Michele Cavo, Robert Z. Orlowski, Jesús F. San Miguel, Antonio Palumbo, Jean-Luc Harousseau

Blood (2012) 120 (5): 947–959.

https://doi.org/10.1182/blood-2012-04-403733

Published: 2012

Journal Articles

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study

Blood (2012) 119 (12): 2943–2948.

https://doi.org/10.1182/blood-2011-05-352989

Published: 2012

Journal Articles

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Blood (2011) 118 (22): 5752–5758.

https://doi.org/10.1182/blood-2011-05-355081

Published: 2011

Journal Articles

A Scoring System Predictive of Extensive Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Stem Cell Transplantation (allo-SCT)

Eolia Brissot, Yohann Foucher, Florent Malard, Zinaida Peric, Aline Clavert, Patrice Chevallier, MD, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Jean-Luc Harousseau, MD, Philippe Moreau, MD, Marianne Coste-Burel, Berthe-Marie Imbert-Marcille, Marc Gregoire, Cécile Braudeau, Régis Josien, Béatrice Gaugler, Mohamad Mohty

Blood (2011) 118 (21): 1980.

https://doi.org/10.1182/blood.V118.21.1980.1980

Published: 2011

Journal Articles

Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT),

Aline Clavert, MD, Peric Zina, MD, Xavier Cahu, MD, Patrice Chevallier, MD, Eolia Brissot, Florent Malard, Thierry Guillaume, Jacques Delaunay, MD, Sameh Ayari, Viviane Dubruille, Beatrice Mahe, Nicolas Blin, MD, Thomas Gastinne, Virginie Roland, Steven Le Gouill, MD, PhD, Jean-Luc Harousseau, Philippe Moreau, MD, Noel Milpied, MD, Mohamad Mohty

Blood (2011) 118 (21): 4100.

https://doi.org/10.1182/blood.V118.21.4100.4100

Published: 2011

NARROW

Potential future direction of measurable residual disease evaluation in multiple myeloma

Sequencing anti-BCMA therapies in myeloma

Requirements for operational cure in multiple myeloma

Up-front ixazomib in older patients with myeloma

Daratumumab in transplant regimens for myeloma?

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Light Chain Escape in Multiple Myeloma

How I treat first relapse of myeloma

Next-generation multiple myeloma treatment: a pharmacoeconomic perspective

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Comparing the Performance of Serum Free Light Chain Measurements with Urine Electrophoresis and Immunofixation for Monitoring and Assessing Response to Therapy in Patients with Multiple Myeloma

Prolonged Fluconazole Prophylaxis Is Not Required In Patients With Acute Leukemias Or Myelodysplastic/Myeloproliferative Disorders After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): A Pair-Matched Analysis

Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs.

Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies

Proteasome inhibitors in multiple myeloma: 10 years later

Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

A Scoring System Predictive of Extensive Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Stem Cell Transplantation (allo-SCT)

Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT),

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only